相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in 18F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma
Julia Driessen et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline
Marshall A. Lichtman et al.
HAEMATOLOGICA (2022)
Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study
Rexhep Durmo et al.
HEMATOLOGICAL ONCOLOGY (2022)
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial
Lutz van Heek et al.
BMC CANCER (2022)
Do all patients with primary refractory/first relapse of HL need autol o gous stem cell transplant?
Alison J. Moskowitz
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2022)
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
Julia Driessen et al.
LEUKEMIA (2022)
Imaging 18F-FDG PET/CT prognostic role in predicting response to salvage therapy in relapsed/refractory Hodgkin's lymphoma
Roya Eisazadeh et al.
CLINICAL IMAGING (2022)
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
Marie Jose Kersten et al.
HAEMATOLOGICA (2021)
Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017
Julia Driessen et al.
LEUKEMIA (2021)
Repeatability of two semi-automatic artificial intelligence approaches for tumor segmentation in PET
Elisabeth Pfaehler et al.
EJNMMI RESEARCH (2021)
How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents
Julia Driessen et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2021)
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
Alison J. Moskowitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031
Sarah A. Milgrom et al.
PEDIATRIC BLOOD & CANCER (2021)
In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection
Sophia Sobesky et al.
MED (2021)
18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome
Anne-Segolene Cottereau et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Intratumor Heterogeneity Assessed by 18F-FDG PET/CT Predicts Treatment Response and Survival Outcomes in Patients with Hodgkin Lymphoma
Kun-Han Lue et al.
ACADEMIC RADIOLOGY (2020)
Correlations between baseline18F-FDG PET tumour parameters and circulating DNA in diffuse large B cell lymphoma and Hodgkin lymphoma
Pierre Decazes et al.
EJNMMI RESEARCH (2020)
RaCaT: An open source and easy to use radiomics calculator tool
Elisabeth Pfaehler et al.
PLOS ONE (2019)
A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma
Sarah A. Milgrom et al.
SCIENTIFIC REPORTS (2019)
Repeatability of 18F-FDG PET radiomic features: A phantom study to explore sensitivity to image reconstruction settings, noise, and delineation method
Elisabeth Pfaehler et al.
MEDICAL PHYSICS (2019)
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
Anne-Segolene Cottereau et al.
BLOOD (2018)
Radiomics Features Differentiate Between Normal and Tumoral High-Fdg Uptake
Chih-Yang Hsu et al.
SCIENTIFIC REPORTS (2018)
Radiomics analysis of pre-treatment [F-18]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment
E. J. van Helden et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Long-Term Outcomes Among 2-Year Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Diffuse Large B-Cell Lymphoma
Regina M. Myers et al.
CANCER (2018)
Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
A. F. Herrera et al.
ANNALS OF ONCOLOGY (2018)
FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
Sally F. Barrington et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma
Fong Chun Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc P. E. Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Peter Borchmann et al.
LANCET (2017)
Radiomics: the bridge between medical imaging and personalized medicine
Philippe Lambin et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
Alison J. Moskowitz et al.
BLOOD (2017)
Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma
P. J. Broeckelmann et al.
ANNALS OF ONCOLOGY (2017)
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
Alison J. Moskowitz et al.
LANCET ONCOLOGY (2015)
Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma
John Radford et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Ronald Boellaard et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant
Bastian von Tresckow et al.
LEUKEMIA & LYMPHOMA (2014)
Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma
Theresa Hahn et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma
Moo-Kon Song et al.
CANCER SCIENCE (2013)
Reference Range for Intrapatient Variability in Blood-Pool and Liver SUV for 18F-FDG PET
Raef R. Boktor et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
Craig H. Moskowitz et al.
BLOOD (2012)
Radiomics: Extracting more information from medical images using advanced feature analysis
Philippe Lambin et al.
EUROPEAN JOURNAL OF CANCER (2012)
Misuse of DeLong test to compare AUCs for nested models
Olga V. Demler et al.
STATISTICS IN MEDICINE (2012)
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
Ronald Boellaard et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
分享论文
